Neutropenia News and Research

RSS

Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils, the most important type of white blood cell, in the blood.

New data from Novartis' ACZ885 Phase III study on SJIA

Novartis announced today new pivotal Phase III data showing 45% of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885.

7 Nov 2011

Allos third quarter net loss decreases to $11.2 million

Allos Therapeutics, Inc. today reported financial results for the three months ended September 30, 2011.

3 Nov 2011

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.

2 Nov 2011

Allos terminates AMAG merger agreement with AMAG

Allos Therapeutics, Inc. announced today that the Agreement and Plan of Merger and Reorganization entered into by and among Allos, AMAG and Alamo Acquisition Sub, Inc. on July 19, 2011, as amended on August 8, 2011, has been terminated.

22 Oct 2011

Delayed appendectomies may increase likelihood of complications in children

An in-hospital delay of appendicitis treatment beyond two days was linked to an increased likelihood of complications, including perforation and abscess formation; longer hospitalization; increased costs; and more rarely, death, according an abstract presented Saturday, Oct. 15 at the American Academy of Pediatrics (AAP) National Conference and Exhibition in Boston.

15 Oct 2011

ApoPharma receives FDA approval for Ferriprox to treat transfusional iron overload

The U.S. Food and Drug Administration today approved Ferriprox (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.

15 Oct 2011

Allos to complete merger with AMAG Pharmaceuticals

Allos Therapeutics, Inc. today announced that it continues to work with AMAG Pharmaceuticals, Inc. towards the completion of their merger, pending stockholder approval and satisfaction of the other conditions to closing described in Allos' definitive proxy statement filed with the SEC on September 15, 2011.

11 Oct 2011

JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer

Celgene International Sàrl today announced that results from a clinical study of ABRAXANE in combination with gemcitabine in 67 patients with previously untreated advanced pancreatic cancer were published in an online article by the Journal of Clinical Oncology ahead of print.

7 Oct 2011

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Merck, known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS (boceprevir), the company's first-in-class, oral hepatitis C virus NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.

1 Oct 2011

Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors

Synta Pharmaceuticals Corp. announced that results of a Phase 1 study of ganetespib in combination with docetaxel in solid tumors were presented at the Annual Meeting of the European Society of Medical Oncology in Stockholm, Sweden.

27 Sep 2011

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Aeterna Zentaris Inc., today announced positive interim data for the Phase 1 portion of its ongoing Phase 1/2 study in castration and taxane-resistant prostate cancer with its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108.

26 Sep 2011

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced the results of the Phase II study TDM4450g in people with previously untreated HER2-positive metastatic breast cancer.

26 Sep 2011

Percutaneous hepatic perfusion extends survival time for melanoma patients

Melanoma of the eye frequently spreads to the liver and, once this has happened, there is no effective treatment and patients die within an average of two to four months. Only about one in ten patients live for a year. Now, final results from a phase III study have demonstrated that a new treatment significantly extends the time patients can live without the disease progressing.

26 Sep 2011

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.

26 Sep 2011

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhea.

26 Sep 2011

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Celgene International Sàrl was notified today that the E.U. Committee for Medicinal Products for Human Use (CHMP), on behalf of the European Medicines Agency (EMA) has concluded an Article 20 review of REVLIMID and issued a positive opinion for the use of REVLIMID in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

23 Sep 2011

ASM to honor LA BioMed investigator for A. baumannii infection study

Ashraf Ibrahim, Ph.D., principal investigator at LA BioMed who specializes in infectious diseases, was recently honored by the American Society for Microbiology (ASM) and the ICAAC Program Committee in the area of Therapy and Prevention of Microbial Disease.

14 Sep 2011

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

Aeterna Zentaris Inc. earlier today, presented positive final Phase 2 efficacy and safety data for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer.

14 Sep 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.

14 Sep 2011

Nektar announces positive results from NKTR-102 Phase 2 study on metastatic breast cancer

Nektar Therapeutics announced today that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer were presented at the ASCO 2011 Breast Cancer Symposium in San Francisco, California.

12 Sep 2011

Neutropenia News and Research

Further Reading

New data from Novartis' ACZ885 Phase III study on SJIA

Allos third quarter net loss decreases to $11.2 million

Takeda receives FDA approval for VELCADE sNDA to treat MM

Allos terminates AMAG merger agreement with AMAG

Delayed appendectomies may increase likelihood of complications in children

ApoPharma receives FDA approval for Ferriprox to treat transfusional iron overload

Allos to complete merger with AMAG Pharmaceuticals

JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Percutaneous hepatic perfusion extends survival time for melanoma patients

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

ASM to honor LA BioMed investigator for A. baumannii infection study

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Nektar announces positive results from NKTR-102 Phase 2 study on metastatic breast cancer

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News